# Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

> **NCT04797780** · PHASE3 · TERMINATED · sponsor: **Syros Pharmaceuticals** · enrollment: 246 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Placebo
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04797780
- **Lead sponsor:** Syros Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-08
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 246 (ACTUAL)
- **Why stopped:** As per Sponsor decision, the study was terminated.
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797780, "Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04797780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*